Picture of Tempus AI logo

TEM — Tempus AI News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Tempus AI Q2 revenue slightly beats estimates

Tempus AI Q2 revenue slightly beats estimates


Overview

  • US precision medicine AI firm's Q2 revenue rose 22% yr/yr, slightly beating analyst expectations

  • Adjusted EBITDA missed estimates

  • Company raised 2026 revenue guidance


Outlook

  • Tempus raises 2026 revenue guidance to $1.595-$1.605 bln

  • Company continues to expect 2026 adjusted EBITDA of ~$65 mln

  • Guidance excludes impact from Personalis acquisition, expected to close late Q4 2026 or early 2027


Result Drivers

  • ONCOLOGY DIAGNOSTICS GROWTH - Co said 31% yr/yr growth in oncology test volume drove diagnostics revenue, with MRD test volume also rising

  • DATA LICENSING DEALS - Co attributed 36% yr/yr growth in Insights revenue and ~$200 mln in new Data and Applications licenses to large deals with pharma clients

  • PRODUCT APPROVALS AND LAUNCHES - Co cited FDA approval of xT Tumor Only assay and launch of Tempus Preview as operational highlights supporting business momentum


Company press release: ID:nBwgr9wla


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Slight Beat*

$382.49 mln

$379.74 mln (16 Analysts)

Q2 Adjusted Loss Per Share

Beat

$0.04

$0.14 (12 Analysts)

Q2 Net Income

$5.64 mln

Q2 Adjusted EBITDA

Miss

$8.04 mln

$8.49 mln (11 Analysts)

Q2 Income from Operations

-$75.91 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Tempus AI Inc is $67.00, about 61.3% above its July 29 closing price of $41.55


Reuters Recommended Reads

  • July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook

  • July 29 - Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates

  • July 30 - Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Tempus AI

See all news